Viracor-IBT Laboratories Acquires Assets of the National Institute of Transplantation

Viracor-IBT Laboratories announced today it has signed a definitive agreement to purchase all assets associated with the laboratory operations of the NIT. The transaction is expected to close in early December 2013, pending regulatory approval. The acquisition will help perpetuate and extend the missions of the NIT and Viracor-IBT, with a goal to improve the lives of more patients across the U.S. Viracor-IBT currently serves approximately sixty percent of the nation’s transplant programs by helping clinicians diagnose and differentiate BMT and SOT complications. NIT’s expertise in pre-transplant testing complements Viracor-IBT’s capabilities in post-transplant diagnostics, providing more full-service transplant diagnostic solutions to patients.

Press-Release_Viracor-IBT-and-NIT_Approved.pdf download View | Download
Categories: MNITF Press